ELAN
NEUTRAL
$22.75
Live
Elanco Animal Health Incorporated · NYSE
Target $28.79
(+26.5%)
$9.32
52W Range
$27.72
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 26, 2026
Market cap
$11.36B
P/E
N/A
ROE
-3.7%
Profit margin
-4.9%
Debt/Equity
0.68
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
ELAN exhibits a critical divergence between market sentiment and fundamental health, highlighted by a very weak Piotroski F-Score of 2/9. While the company has seen a massive 1-year price surge of 140.5% and maintains strong analyst support (Strong Buy), the underlying financials show negative profit margins and negative ROE. Revenue growth remains positive at 12.2%, and the company consistently beats earnings estimates, but the high PEG ratio of 3.83 suggests the stock is significantly overvalued relative to its actual growth. The outlook is neutral as the market bets on a turnaround that the current deterministic health scores do not yet support.
Key Strengths
Strong Gross Margin of 55.00%
Consistent track record of beating earnings estimates (3/4 last 4 quarters)
Positive YoY and Q/Q revenue growth (~12%)
Healthy liquidity with a Current Ratio of 2.17
Strong analyst consensus with a target price of $28.79
Key Risks
Very weak Piotroski F-Score (2/9) indicating deteriorating financial health
Negative Profit Margin (-4.92%) and negative ROE (-3.67%)
High PEG Ratio (3.83) indicating overvaluation relative to growth
Negative YoY EPS growth (-7.1%)
Bearish short-term technical trend (1-month change of -10.8%)
AI Fair Value Estimate
Based on comprehensive analysis
$20.5
-9.9% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
35
Weak
40
55
60
20
0
AI Verdict
Speculative Recovery
Key drivers: Revenue growth, Earnings surprises, Poor fundamental health scores, Overvaluation relative to growth
Confidence
85%
Value
40/100
Ref P/E, PEG, Graham Number
Positives
- Forward P/E of 19.47 is moderate
Watchpoints
- PEG ratio of 3.83 is excessively high
- Price/Book of 1.73
Future
55/100
Ref Growth rates
Positives
- 12.2% Revenue growth
- Strong analyst target prices
Watchpoints
- Negative EPS growth
- Lack of clear intrinsic value growth
Past
60/100
Ref Historical trends
Positives
- Exceptional 1-year price performance (+140.5%)
- Consistent history of earnings beats
Watchpoints
- Negative 5-year change (-26.6%)
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Manageable Debt/Equity (0.68)
- Strong Current Ratio (2.17)
Watchpoints
- Piotroski F-Score of 2/9 is a major red flag
- Negative Profit Margin and ROE
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$22.75
Analyst Target
$28.79
Upside/Downside
+26.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ELAN and closest competitors.
Updated 2026-04-24
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Incorporated
Primary
|
-26.6% | +143.8% | +140.5% | +3.2% | -10.8% | -3.9% |
|
GH
Guardant Health, Inc.
Peer
|
-43.8% | +265.0% | +98.7% | +33.6% | -3.7% | -7.1% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-27.4% | -41.9% | -20.1% | +4.3% | -5.4% | +4.4% |
ELA
Elanco Animal Health Incorporated
Primary
5Y
-26.6%
3Y
+143.8%
1Y
+140.5%
6M
+3.2%
1M
-10.8%
1W
-3.9%
GH
Guardant Health, Inc.
Peer
5Y
-43.8%
3Y
+265.0%
1Y
+98.7%
6M
+33.6%
1M
-3.7%
1W
-7.1%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
EXE
Exelixis, Inc.
Peer
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
BMR
BioMarin Pharmaceutical Inc.
Peer
5Y
-27.4%
3Y
-41.9%
1Y
-20.1%
6M
+4.3%
1M
-5.4%
1W
+4.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
19.47
PEG Ratio
3.83
P/B Ratio
1.73
P/S Ratio
2.41
EV/Revenue
3.23
EV/EBITDA
16.75
Market Cap
$11.36B
Profitability
Profit margins and return metrics
Profit Margin
-4.92%
Operating Margin
2.27%
Gross Margin
55.0%
ROE
-3.67%
ROA
1.25%
Growth
Revenue and earnings growth rates
Revenue Growth
+12.2%
Earnings Growth
N/A
Q/Q Revenue Growth
+12.16%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.68
Moderate
Current Ratio
2.17
Strong
Quick Ratio
1.0
Good
Cash/Share
$1.1
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.1B
Gross Margin
51.5%
Op. Margin
1.7%
Net Margin
-24.1%
Total Assets
$13.4B
Liabilities
$6.8B
Equity
$6.5B
Debt/Equity
1.04x
Operating CF
$0.1B
CapEx
$-0.1B
Free Cash Flow
$0.0B
FCF Yield
43%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-24
$0.13
+11.2% surprise
2025-11-05
$0.19
+43.9% surprise
2025-08-07
$0.26
+29.5% surprise
Healthcare Sector Comparison
Comparing ELAN against 548 companies in the Healthcare sector
(30 bullish, 163 neutral, 355 bearish)
Return on Equity (ROE)
-3.67%
This Stock
vs
-89.9%
Sector Avg
-95.9%
(Below Avg)
Profit Margin
-4.92%
This Stock
vs
-16.4%
Sector Avg
-70.0%
(Weaker)
Debt to Equity
0.68
This Stock
vs
2.71
Sector Avg
-75.0%
(Less Debt)
Revenue Growth
12.2%
This Stock
vs
126.74%
Sector Avg
-90.4%
(Slower)
Current Ratio
2.17
This Stock
vs
4.53
Sector Avg
-52.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Incorporated
|
NEUTRAL | $11.36B | - | -3.7% | -4.9% | $22.75 | |
|
GH
Guardant Health, Inc.
|
NEUTRAL | $11.43B | - | -% | -42.4% | $87.17 | Compare |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.86B | 32.28 | 5.9% | 10.8% | $56.49 | Compare |
ELAN
Elanco Animal...
NEUTRAL
Mkt Cap
$11.4B
P/E
-
ROE
-3.7%
Price
$22.75
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | DE BRABANDER ELLEN | Officer | Stock Award | 40,985 | - |
| 2026-02-27 | SIMMONS JEFFREY N. | Chief Executive Officer | Stock Award | 516,360 | - |
| 2026-02-27 | VANHIMBERGEN ROBERT M | Chief Financial Officer | Stock Award | 23,675 | - |
| 2026-02-27 | CABRAL RAMIRO MARTIN | Officer | Stock Award | 80,887 | - |
| 2026-02-27 | KINARD DAVID S | Officer | Stock Award | 42,557 | - |
| 2026-02-27 | MEER JAMES M | Officer | Stock Award | 14,805 | - |
| 2026-02-27 | BETTINGTON TIMOTHY J | Officer | Stock Award | 55,792 | - |
| 2026-02-27 | CORREIA DE SIMAS JOSE MANUEL | Officer | Stock Award | 32,871 | - |
| 2026-02-27 | DE BRABANDER ELLEN | Officer | Stock Award | 92,924 | - |
| 2026-02-27 | MODI RAJEEV A | Officer | Stock Award | 55,895 | - |
| 2026-02-27 | MC-ARDLE GERALD | Officer | Stock Award | 44,315 | - |
| 2026-02-27 | O'NEILL SHIV | General Counsel | Stock Award | 47,766 | - |
| 2025-12-19 | HOOVER R DAVID | Director | Gift | 60,000 | - |
| 2025-12-12 | KURZIUS LAWRENCE ERIK | Director | Purchase | 10,000 | $213,000 |
| 2025-12-11 | SIMMONS JEFFREY N. | Chief Executive Officer | Purchase | 22,000 | $478,496 |
DE BRABANDER ELLEN
Officer
2026-04-01
40,985 shares
SIMMONS JEFFREY N.
Chief Executive Officer
2026-02-27
516,360 shares
VANHIMBERGEN ROBERT M
Chief Financial Officer
2026-02-27
23,675 shares
CABRAL RAMIRO MARTIN
Officer
2026-02-27
80,887 shares
KINARD DAVID S
Officer
2026-02-27
42,557 shares
MEER JAMES M
Officer
2026-02-27
14,805 shares
BETTINGTON TIMOTHY J
Officer
2026-02-27
55,792 shares
CORREIA DE SIMAS JOSE MANUEL
Officer
2026-02-27
32,871 shares
DE BRABANDER ELLEN
Officer
2026-02-27
92,924 shares
MODI RAJEEV A
Officer
2026-02-27
55,895 shares
MC-ARDLE GERALD
Officer
2026-02-27
44,315 shares
O'NEILL SHIV
General Counsel
2026-02-27
47,766 shares
HOOVER R DAVID
Director
2025-12-19
60,000 shares
KURZIUS LAWRENCE ERIK
Director
2025-12-12
10,000 shares
·
$213,000
SIMMONS JEFFREY N.
Chief Executive Officer
2025-12-11
22,000 shares
·
$478,496
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
ELAN filed its 10-K for the fiscal year ended December 31, 2025, on February 24, 2026. The filing includes required disclosures regarding the company's business operations, risk factors, and management's discussion and analysis of financial condition. Specific financial highlights and risk details were not provided in the available excerpts.
8-K
10-Q
8-K
8-K
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
14 analysts
Citigroup
2026-04-15
Buy
Morgan Stanley
2026-02-25
Equal-Weight
Equal-Weight
Keybanc
2026-02-25
Overweight
Overweight
Leerink Partners
2026-02-24
Outperform
Outperform
JP Morgan
2026-02-19
Overweight
Overweight
Piper Sandler
2026-01-22
Neutral
Overweight
Morgan Stanley
2025-12-18
Equal-Weight
Equal-Weight
Barclays
2025-12-09
Overweight
Keybanc
2025-11-21
Overweight
UBS
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning ELAN from our newsroom.
Newest → oldest
No matching news yet.